Clinical Report: Ligneous Conjunctivitis and PLGD-1 Diagnosis and Treatment
Overview
Ligneous conjunctivitis is the predominant ocular manifestation of plasminogen deficiency type 1 (PLGD-1), a systemic disorder causing mucosal ligneous lesions. The FDA-approved treatment RYPLAZIM has demonstrated significant efficacy in resolving lesions and improving patient quality of life.
Background
PLGD-1 is a rare systemic protein deficiency characterized by the formation of ligneous lesions on mucosal membranes, often leading to inflammation, pain, and organ dysfunction including vision impairment. Ligneous conjunctivitis occurs in 81% of PLGD-1 patients and may present as recurrent pseudomembranous conjunctivitis resistant to standard treatments. Diagnosis is challenging due to symptom variability and multisystem involvement, often requiring genetic testing and plasminogen activity assays. Early recognition and treatment are critical to prevent progression and complications.
Data Highlights
| Parameter | Value |
|---|---|
| Ocular involvement in PLGD-1 patients | 81% |
| Plasminogen activity in patient case | 26% |
| Resolution of external lesions by week 48 (RYPLAZIM trial) | 78% |
| Resolution of internal lesions by week 48 (RYPLAZIM trial) | 75% |
| Follow-up duration with no new/recurring lesions | 5 years |
Key Findings
- Ligneous conjunctivitis is the most common clinical sign of PLGD-1, presenting in 81% of patients.
- PLGD-1 symptoms are diverse and often misattributed, delaying diagnosis; genetic testing and plasminogen activity assays are essential for confirmation.
- Standard treatments for conjunctivitis are ineffective in PLGD-1-related lesions, necessitating specialized therapy.
- RYPLAZIM, a plasma-derived human plasminogen, has shown high efficacy with 78% of external and 75% of internal lesions resolving by 48 weeks.
- Long-term follow-up (5 years) shows no new or recurring lesions in patients treated with RYPLAZIM.
- Administration via injection port and parental training facilitates ongoing biweekly treatment, improving patient quality of life.
Clinical Implications
Clinicians should consider PLGD-1 in patients with recurrent or chronic pseudomembranous conjunctivitis unresponsive to conventional therapies and initiate plasminogen activity testing. Early diagnosis and treatment with RYPLAZIM can prevent lesion progression, organ dysfunction, and improve functional outcomes. Multidisciplinary coordination is important due to the systemic nature of PLGD-1.
Conclusion
PLGD-1 is a rare but serious systemic disorder with significant ocular involvement manifesting as ligneous conjunctivitis. The availability of RYPLAZIM offers an effective therapeutic option that can substantially improve patient outcomes and quality of life.
References
- Zhu AY, 2025 -- Patient Casebook Series: Ligneous Conjunctivitis -- Identifying and Treating a Rare Disease
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.